公开(公告)号：US20220137052A1

公开(公告)日：2022-05-05

申请号：US17575137

申请日：2022-01-13

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Carolin ANDERS ,  Martin HUND ,  Ursula-Henrike WIENHUES-THELEN

IPC: G01N33/577

Abstract: The present invention relates to methods of assessing whether a patient has endometriosis or is at risk of developing endometriosis, to methods of selecting a patient for therapy, and method of monitoring a patient suffering from endometriosis or being treated for endometriosis by determining the amount or concentration of Substance P in a sample of the patient, and comparing the determined amount or concentration to a reference.

公开(公告)号：US20220034910A1

公开(公告)日：2022-02-03

申请号：US17403078

申请日：2021-08-16

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Christian ZAUGG ,  Dirk BLOCK ,  Ursula-Henrike WIENHUES-THELEN ,  Hans-Peter BRUNNER ,  Friedemann KRAUSE ,  Fabian MODEL ,  Vincent ROLNY

IPC: G01N33/68

Abstract: The present invention relates to a method for identifying a subject being eligible to the administration of at least one medicament selected from the group consisting of a beta blocker, an aldosterone antagonist, a diuretic, and an inhibitor of the renin-angiotensin system. The method is based on the determination of the amount of at least one biomarker selected from the group consisting of GDF-15 (Growth Differentiation Factor 15), endostatin, mimecan, IGFBP7 (IGF binding protein 7), a cardiac Troponin, a BNP-type peptide, uric acid, Gal3 (Galectin-3), osteopontin, sST2 (soluble ST2), PlGF, sFlt-1, P1NP, Cystatin C, Prealbumin, and Transferrin in a sample from a subject suffering from heart failure. Further, the method comprises the step of comparing the, thus, determined amount with a reference amount. Further envisaged by the present invention are kits and devices adapted to carry out the method of the present invention. The present invention also relates to a system for identifying a subject being eligible to the administration of at least one medicament as disclosed herein and to reagents and kits used in performing the methods as disclosed herein.

公开(公告)号：US20220229075A1

公开(公告)日：2022-07-21

申请号：US17613353

申请日：2020-05-22

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Kai HABBEN ,  Vinzent ROLNY ,  Anika MANG ,  Ursula-Henrike WIENHUES-THELEN ,  Serge MASSON

IPC: G01N33/74 ,  G01N33/68

Abstract: The present invention relates to a method for differentiating between heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF) in a subject suffering from heart failure, said method comprising the steps of determining the amounts of IGFBP7 (Insulin-like growth factor-binding protein 7), of a BNP-type peptide, and optionally of CRP (C-reactive protein) in a sample from the subject, calculating (i) a ratio of the amount of IGFBP7 and the amount of the BNP-peptide or (ii) a ratio of the sum of the amounts of IGFBP7 and CRP and the amount of the BNP-type peptide, comparing the ratio calculated with a reference ratio, and differentiating between heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). The present invention further concerns a method for the diagnosis of HFpEF.

公开(公告)号：US20220206015A1

公开(公告)日：2022-06-30

申请号：US17693789

申请日：2022-03-14

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Dirk BLOCK ,  Hanspeter BRUNNER ,  Thomas DIETERLE ,  Ursula-Henrike WIENHUES-THELEN ,  Christian ZAUGG ,  Andre ZIEGLER

IPC: G01N33/68 ,  A61K31/40 ,  G01N33/62

Abstract: The present invention is directed to a method of identifying a patient having heart failure as likely to respond to a therapy comprising a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein said patient has heart failure and undergoes a therapy comprising a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.